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Abstract
Background: Non-equivalence in serum creatinine (SCr) measurements across Dutch laboratories and the
consequences hereof on chronic kidney disease (CKD) staging were examined.
Methods: National data from the Dutch annual external quality organization of 2009 were used. 144 participating
laboratories examined 11 pairs of commutable, value-assigned SCr specimens in the range 52–262 μmol/L, using
Jaffe or enzymatic techniques. Regression equations were created for each participating laboratory (by regressing
values as measured by participating laboratories on the target values of the samples sent by the external quality
organization); area under the curves were examined and used to rank laboratories. The 10th and 90th percentile
regression equation were selected for each technique separately. To evaluate the impact of the variability in SCr
measurements and its eventual clinical consequences in a real patient population, we used a cohort of 82424
patients aged 19–106 years. The SCr measurements of these 82424 patients were introduced in the 10th and
90th percentile regression equations. The newly calculated SCr values were used to calculate an estimated
glomerular filtration rate (eGFR) using the 4-variable Isotope Dilution Mass Spectrometry traceable Modification of
Diet in Renal Disease formula. Differences in CKD staging were examined, comparing the stratification outcomes
for Jaffe and enzymatic SCr techniques.
Results: Jaffe techniques overestimated SCr: 21%, 12%, 10% for SCr target values 52, 73 and 94 μmol/L, respectively.
For enzymatic assay these values were 0%, -1%, -2%, respectively. eGFR using the MDRD formula and SCr
measured by Jaffe techniques, staged patients in a lower CKD category. Downgrading to a lower CKD stage
occurred in 1-42%, 2-37% and 12–78.9% of patients for the 10th and 90th percentile laboratories respectively in
CKD categories 45–60, 60–90 and >90 ml/min/1.73 m2. Using enzymatic techniques, downgrading occurred only
in 2-4% of patients.
Conclusions: Enzymatic techniques lead to less variability in SCr measurements than Jaffe techniques, and
therefore result in more accurate staging of CKD. Therefore the specific enzymatic techniques are preferably used
in clinical practice in order to generate more reliable GFR estimates.
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Background
Serum creatinine (SCr) based prediction equations are
frequently used in screening and clinical settings in
order to estimate the glomerular filtration rate (GFR).
The current variability in SCr measurements affects all
estimating equations for GFR, including the MDRD
equation. Many automated routine methods for SCr
measurement exceed the desirable imprecision criterion
of ≤ 2.2%; therefore, reduction of analytical bias≤ 3.4%
in creatinine assays by standardization of calibration is
needed [1]. It is important to notice that standardization
of calibration does not correct for analytical interfer-
ences (nonspecificity bias). The bias and nonspecificity
problems associated with some of the routine methods
must be addressed.
Chronic kidney disease (CKD) staging directly relies
on these estimated GFR values. Using accurate SCr mea-
surements is essential, since systematic errors cause
unreliable renal function estimates, leading to incorrect
drug dose adjustments, misclassifications in CKD staging
and incomparability of patient data [2-5].
Since significant interlaboratory variation was observed
worldwide, it was internationally confirmed that calibra-
tion traceability to higher-order reference methods was
needed to realize comparable biochemical measurement
results [2,6,7].
Therefore, the European in vitro diagnostics (IVD) dir-
ective 98/79/EC, and the laboratory working group of
the National Kidney Disease Education Program recom-
mend that in order to improve standardization, clinical
laboratory measurements should be traceable to inter-
nationally recognized and certified reference materials
[8-10]. Since the development of NIST SRM 967 in
2006, a matrix-based IDMS targeted creatinine standard,
all essential elements (i.e. reference methods, reference
laboratories, and materials) needed to complete the cre-
atinine reference system are in place, according to ISO
17511 [11]. Because the complete traceability train is
agreed upon in vitro diagnostic manufactures of creatin-
ine assays in Europe are legally obliged to make their
products metrologically traceable, regardless of the
method applied.
In this study we examine the degree of variability and
interchangeability of SCr measurements across all clin-
ical chemistry laboratories in 2009 in the Netherlands,
in order to evaluate the situation after global restandar-
dization, using data from the annual national external
quality control program of the Dutch external quality
assessment (EQA) organization for clinical chemistry
laboratories (Stichting Kwaliteitsbewaking Medische
Laboratoriumdiagnostiek, SKML). Subsequently, we in-
vestigate in a theoretical model, the impact of the vari-
ability in SCr measurements between laboratories on
estimates of GFR using the 4-variable IDMS-traceable
MDRD formula and the consequences hereof on CKD
staging of patients, when the data from the SKML are
extrapolated to a large cohort of patients.
Methods
In this cross-sectional study, we evaluate the effect of
different SCr assays on SCr levels and CKD classifica-
tion. EQA data are derived from the 2009 EQA program
of the SKML. Annually, the SKML creates 11 pairs
of frozen commutable, value assigned serum samples
spiked with crystalline creatinine, aliquoted in 1 ml vials.
A commutable material reflects the characteristics and
properties of native patient samples [2,12]. Value-
assignment was performed by a joint committee on
traceability in laboratory medicine (JCTLM)-endorsed
reference laboratory. Each of the 144 laboratories
participating in the EQA program in the Netherlands
annually receives a set containing 11 pairs of these com-
mutable samples from the SKML and store them inter-
mittently at −80°C. The 11 pairs of EQA-samples cover
SCr values in the entire measuring range: 52-73-94-115-
136-157-178-199-220-241-262 μmol/L and form a linear
sequence; thus each laboratory received and analyzed,
the range mentioned before in twofold over the year.
The target values for the SCr levels are established by a
JCTLM listed reference laboratory (Bonn, Germany)
using an Isotope Dilution Gas Chromatography/Mass
Spectrometry (ID-GC/MS) method [13,14].
Every other week all routine laboratories thawed one
of the EQA samples and measured the SCr concentra-
tion applying their routine SCr methods according
to the manufacturer’s instructions. 91 (63%) versus 48
(33%) of the laboratories used a Jaffe or enzymatic
method to measure SCr, respectively. 62 (68%) laborator-
ies using a Jaffe technique applied a modified kinetic Jaffe
method; 29 (32%) used a compensated Jaffe method. Few
laboratories used dry chemistry to measure SCr; since this
group of laboratories was too small to draw conclusions
from (n= 5), this group was excluded from further
analyses. Companies and instruments included Abbott
(Abott Park, Il, USA; Aeroset, Architect), Beckman (Brea,
Ca, USA; Synchron, Unicel, LX20, Lxi725), Siemens Health-
care diagnostics (The Netherlands; ADVIA 1650, 1800,
2400), Roche Diagnostics (Mannheim, Germany; Integra,
Hitachi, Modular, Cobas, Cobas Integra) and Olympus
(Tokyo, Japan; AU 400, 600). In total, 39 different instru-
ment method combinations were used to measure SCr.
Data of the SCr measurements as measured by the
participating laboratories were reported centrally to the
SKML and collected in an completely anonymous database.
Variability SCr extrapolated in cohort
To investigate the impact of the variability in SCr mea-
surements as found in the national EQA database
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and the eventual clinical consequences hereof in a real
patient population, we used an unselected cohort of
82424 patients whose SCr had been measured in 2009 in
the Isala Clinics Zwolle, the Netherlands; the details of
this population have been described before [15]. In
short, 45.3% of the population was male, age varied from
19–106 years and 38.7% was older than 65 years old.
SCr in this cohort was measured using an enzymatic
technique (modular P Analyzer, creatinine plus assay;
Roche Diagnostics, Mannheim, Germany). In order to
obtain SCr reference values that are traceable to the
reference data from the EQA program for each patient,
we requested the results from the 2009 EQA program
from the clinical chemistry department, Isala clinics
Zwolle. Based on these results we created a regression
equation for the Zwolle laboratory (the exact procedure
is extensively described in the statistical analyses sec-
tion), using inverse regression. Subsequently SCr values
as measured in the Zwolle population were introduced
in this regression equation in order to calculate the SCr
values traceable to the results of the EQA program for
each of the 82424 patients. The GFR using these IDMS-
traceable SCr values was estimated using the 4-variable
IDMS-traceable MDRD formula [16,17].
Statistical analysis
We used SPSS version 16.0 (SAS Institute, Cary, NC,
USA) and STATA version 11 (StataCorp, College Station,
Texas USA) for statistical analyses. All SCr measure-
ments of the laboratories participating in the EQA pro-
gram were inspected for outliers (truncated at ± 3
standard deviation (SD)); 3 laboratories were removed
from the dataset because more than 50% of the measure-
ments of these 3 laboratories deviated more than 3 SD
from the other laboratories. The target reference values
from the linearity sequence of the EQA program served
as the reference method against which routine methods
to measure SCr from participating laboratories were
compared, by means of relative and absolute bias. The
results were displayed in box and whisker plots for each
method group. Relative bias is defined as the mean
percentage difference [(measured SCr-target value SCr)/
target value SCr] x 100; absolute bias is defined as the
mean difference between SCr values measured by indi-
vidual laboratories and SCr target values; precision is
defined as the SD of the absolute bias.
We extrapolated the impact of the non-equivalence in
SCr measures (as derived from the laboratories partici-
pating in the EQA program), to our patient cohort
of 82424 patients. In order to do so, SCr values as mea-
sured by laboratories participating in the quality assess-
ment program were regressed on the target values of
the samples sent by the SKML, so-called inverse regres-
sion, for each of the participating laboratories
separately. Regression equations for each of the partici-
pating laboratories, (n = 47 for Jaffe and n = 39 for en-
zymatic), who had not changed their technique to
measure SCr in 2009, were created. For each of these re-
gression equations (thus for each of the laboratories ful-
filling the criteria mentioned above), we calculated an
area under the curve (AUC) in the range 73–115 μmol/
L. The range of 73–115 μmol/L was chosen since espe-
cially these values of SCr provide eGFR’s around the
threshold value of 60 ml/min/1.73 m2, sufficient to clas-
sify patients as having CKD stage 3. Subsequently, the
AUC’s of all the participating laboratories were ranked
in ascending order for the Jaffe and the enzymatic tech-
nique separately, in order to establish a 10th and 90th
percentile regression equation for each of the techni-
ques. Then, SCr values from our cohort of 82424
patients were inserted in the 10th and 90th percentile re-
gression equations (for the Jaffe technique and the en-
zymatic technique as appropriate). These ‘newly
calculated’ SCr values were introduced in the appropri-
ate MDRD equations, thus providing 10th and 90th per-
centile eGFR values. To get an impression from the
clinical implications of the variation in SCr values on
CKD staging, we classified the patients according to the
K/DOQI guidelines and evaluated the differences in
CKD staging when SCr values were measured by Jaffe or
the enzymatic methods [18].
Ethical statement
No permission was required from the Medical Ethics
Committee as our data only included lab result informa-
tion, which had been obtained from a laboratory data-
base. No personal patient information was included.
Permission to use the national 2009 EQA-data was
obtained from the SKML. The laboratories in the dataset
were anonymous.
Results
The relative and absolute bias for both Jaffe and enzym-
atic techniques are shown in Figures 1, 2, 3 and 4. The
enzymatic method to measure SCr produced the least
biased results, which were not significantly different
from the target values, whereas the Jaffe technique
produced the most biased and imprecise results, which
differed significantly from the reference values. The
Jaffe technique especially tended to overestimate SCr
at low concentrations: 21%, 12%, 10% for the SCr
target values 52, 73 and 94 μmol/L, respectively. The
enzymatic method had a small bias that was constant
over the entire range of SCr values. The precision
for Jaffe/enzymatic (per reference value) is: 10/3
(52 μmol/L), 10/3 (73 μmol/L), 7/3 (94 μmol/L), 13/4
(115 μmol/L), 7/5 (136 μmol/L), 8/4 (157 μmol/L), 8/5
(178 μmol/L), 9/5 (199 μmol/L), 10/6 (220 μmol/L),
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11/5 (241 μmol/L), 5/2 (262 μmol/L) for both the Jaffe
and the enzymatic method.
The impact of the variability in SCr measurements on
CKD staging is illustrated in Tables 1 and 2. From the
tables we can conclude that the differences between the
10th and 90th percentile laboratory are large when a Jaffe
technique is used. Downgrading to a lower CKD class
was observed using the Jaffe assay for CKD stages: 45–
60 ml/min/1.73 m2 (1.1%, 41.9%); 60–90 ml/min/
1.73 m2 (1.8, 36.7%) and >90 ml/min/1.73 m2 (12.3%,
78.9%), for the 10th and 90th percentile values respect-
ively. When an enzymatic technique was used, the vari-
ability resulted in both upward and downward
reclassification of CKD stage. Downward reclassification
occurred in 2.1-4.1% of patients, whereas upgrading
occurred in 15.6-30.1% of patients.
Discussion
The present study shows that interlaboratory non-
equivalence in SCr assays in the Netherlands was still
substantial in 2009, notwithstanding the recent inter-
national creatinine restandardization effort. The high
variability was largely explained by the ongoing use of
Jaffe assays for measuring SCr. Compared to the enzym-
atic assays, the Jaffe assays had a significantly larger bias,
especially for SCr levels in the lower range (reference
value range 52–115 μmol/L). Although relative bias
decreased when SCr reference values were higher,
imprecision remained high. It was of course to be
expected that Jaffe methods lead to a positive bias com-
pared to the ID-/GC-MS method, and that adjustment
for this bias would occur when using the appropriate
MDRD equation. This has caused the downgrading
of patients to a lower CKD category relevantly more often
when a Jaffe technique instead of an enzymatic technique
was used, especially in categories >45 ml/min/1.73 m2
(up to 79%). In contrast, the use of an enzymatic technique
more often resulted in upgrading of the CKD stage, which
may be explained by the differences in bias: the Jaffe tech-
nique provided higher values of SCr, whereas the enzym-
atic technique provided slightly lower values.
Ever since SCr is assessed in clinical practice its accur-
acy has been debated [1,7,19]. Although, SCr measure-
ments are routinely performed, it is one of the most
variable laboratory tests [20]. The increasing use of
eGFR in clinical practice has renewed the interest on the
shortcomings of the SCr methodology [1,21-24]. Since
SCr is the most important variable in the renal function
estimation equations, calibration of the creatinine assays
is necessary to reduce bias in these formulas. This even
lead to a modification of the factor used in the MDRD-
equation (from 186 to 175 for IDMS traceable creatin-
ine). However, the way this calibration was obtained has
been regularly criticized in literature, due to the fact that
Figure 1 Box and whisker plot showing the percentual bias of
the Jaffe technique. Box and whisker plot showing the percentual
bias for the Jaffe technique . Interpretation of the vertical axis e.g.
1.1 means a percentual bias of 10%. The box represents the 25th,
50th and 75th percentile; the whiskers represent the 5th and 95th
percentile. The extremes, defined as values more than three times
the interquartile range, are the signs above and underneath the
whiskers. The grey line represents the 0% bias line.
Figure 2 Box and whisker plot showing the percentual bias of
the enzymatic technique. Box and whisker plot showing the
percentual bias for the enzymatic technique (1). Interpretation of the
vertical axis e.g. 1.1 means a percentual bias of 10%. The box
represents the 25th, 50th and 75th percentile; the whiskers represent
the 5th and 95th percentile. The extremes, defined as values more
than three times the interquartile range, are the signs above and
underneath the whiskers. The grey line represents the 0% bias line.
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the formulas were modified after having recalibrated the
Jaffe creatinine to an IDMS traceable enzymatic method,
having deleted the intercepts since these were not statis-
tically significant.
The substantial bias and between laboratory variance
as we found in our study, has been shown in various
other studies in which data from proficiency testing (PT)
and EQA scheme programs were evaluated [7,25,26].
A European trueness verification study of SCr also
showed large interlaboratory variability before the
matrix-based SRM 967 standard was available [7]. In our
study we would have expected a significantly reduced
interlaboratory CV due to global restandardization on
SRM 967. However, despite the European IVD directive
with stricter regulations, no improvements compared
to earlier studies, in which a method group SD of 2.6-
11 μmol/L and a median CV of 5% at a SCr concentra-
tion of 74 μmol/L, had been reached [27]. The failure to
realize amelioration of interlaboratory non-equivalence
is explained by the fact that standardization does not
correct for analytical non-specificity problems, as is the
case with the Jaffe method [28,29]. These non-specificity
problems concern the measurement of many endogen-
ous and exogenous interfering substances such as pro-
tein, glucose and ketones when SCr is measured using a
Jaffe method [28-31]. Despite many attempts to improve
the performance characteristics of the Jaffe reaction,
non-specificity remained [7]. This leads to overesti-
mation of the true SCr concentration. Calibration trace-
ability cannot solve this problem nor substitute for
improvement of suboptimal routine methods.
Although the enzymatic assay to measure SCr is not
free of interference from various substances, it has a bet-
ter specificity than the Jaffe technique [28]. This was re-
cently confirmed in a multicentre study evaluating
IDMS-traceable enzymatic creatinine assays. It showed
that the majority of enzymatic methods reached the
acceptable total analytical error of 8% for SCr values as
low as 36 μmol/L, when adequately calibrated against
IDMS, improving the traceability and standardization of
creatinine [32].
Moreover, upgrading in CKD stage as we observed
when enzymatic assays were used in the MDRD formula
may be less relevant in routine clinical practice than the
downgrading to a lower CKD stage as occurs when
a Jaffe assay was used to measure SCr. E.g. a patient
whose eGFR is 57 ml/min/1.73 m2 (CKD stage 3a) or
62 ml/min/1.73 m2 (CKD stage 2) when a Jaffe respect-
ively an enzymatic assay is used to examine SCr, prob-
ably have similar risks regarding end-stage renal disease,
all-cause and cardiovascular mortality. From studies
comparing the prognosis associated with the two most
commonly used equations to estimate GFR (the MDRD
and the Chronic Kidney Disease Epidemiology collabor-
ation equation, CKD-EPI) during a long follow-up
(≥7.5 years) we know that individuals reclassified from
CKD stage 3a (eGFR 45–60 ml/min/1.73 m2) to no CKD
had lower mortality risk than those not reclassified.
Figure 4 Box and whisker plot showing the absolute bias
(μmol/L) for the enzymatic technique. The box represents the
25th, 50th and 75th percentile; the whiskers represent the 5th and
95th percentile. The extremes, defined as values more than three
times the interquartile range, are the signs above and underneath
the whiskers. The grey line represents the 0 μmol/L bias line.
Figure 3 Box and whisker plot showing the absolute bias
(μmol/L) for the Jaffe technique. The box represents the 25th,
50th and 75th percentile; the whiskers represent the 5th and 95th
percentile. The extremes, defined as values more than three times
the interquartile range, are the signs above and underneath the
whiskers. The grey line represents the 0 μmol/L bias line.
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Table 1 Implications for CKD staging when a Jaffe or a standardized serumcreatinine is used
MDRD Jaffe p10 / p90
<30 ml/min/1.73 m2 30-45 ml/min/1.73 m2 45-60 ml/min/1.73 m2 60-90 ml/min/1.73 m2 >90 ml/min/1.73 m2 Total
p10 p90 p10 p90 p10 p90 p10 p90 p10 p90
MDRD
standardized
<30 ml/min/1.73 m2 2523 (99.2%) 2543 (100%) 20 (0.8%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2543
30-45 ml/min/1.73 m2 0 (0%) 678 (17.3%) 3908 (100%) 3231 (82.7%) 1 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3909
45-60 ml/min/1.73 m2 0 (0%) 0 (0%) 90 (1.1%) 3439 (41.9%) 8126 (98.9%) 4777 (58.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 8216
60-90 ml/min/1.73 m2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 736 (1.8%) 14598 (36.7%) 39085 (98.2%) 25223 (63.3%) 0 (0%) (0%) 39821
>90 ml/min/1.73 m2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3448 (12.3%) 22047 (78.9%) 24487 (87.7%) 5888 (21.1%) 27935
2523 3221 4018 6670 8863 19375 42533 47270 24487 5888 82424
Crosstabulation showing the estimated glomerular filtration rate (GFR) stages when the modification of diet in renal disease equation (MDRD) is calculated with a standardized serumcreatinine versus a serumcreatinine
as measured by a p10 (10th percentile) or a p90 (90th percentile) laboratory using a Jaffe technique.
Table 2 Implication for CKD staging when an enzymatic or a standardized serumcreatinine is used
MDRD enzymatic p10 / p90
<30 ml/min/1.73 m2 30-45 ml/min/1.73 m2 45-60 ml/min/1.73 m2 60-90 ml/min/1.73 m2 >90 ml/min/1.73 m2 Total
p10 p90 p10 p90 p10 p90 p10 p90 p10 p90
MDRD
standardized
<30 ml/min/1.73 m2 2483 (97.6%) 2543 (100%) 60 (2.4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2543
30-45 ml/min/1.73 m2 0 (0%) 141 (3.6%) 3299 (84.4%) 3768 (96.4%) 610 (15.6%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3909
45-60 ml/min/1.73 m2 0 (0%) 0 (0%) 0 (0%) 338 (4.1%) 5740 (69.9%) 7878 (95.9%) 2476 (30.1%) 0 (0%) 0 (0%) 0 (0%) 8216
60-90 ml/min/1.73 m2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 845 (2.1%) 28308 (71.1%) 38976 (97.9%) 11513 (28.9%) 0 (%) 39821
>90 ml/min/1.73 m2 5 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1502 (5.4%) 27930 (100%) 26433 (94.6%) 27935
2488 2684 3359 4106 6350 8723 30784 40478 39443 26433 82424
Crosstabulation showing the estimated glomerular filtration rate (GFR) stages when the modification of diet in renal disease equation (MDRD) is calculated with a standardized serumcreatinine versus a serumcreatinine
as measured by a p10 (10th percentile) or a p90 (90th percentile) laboratory using an enzymatic technique.
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Moreover, these participants had an equal risk to those
classified as no CKD by both formulas [33,34].
Based on the large batch of evidence in literature show-
ing that alkaline picrate methods are inferior methods to
measure creatinine, it is time for laboratories to substitute
the alkaline picrate method by enzymatic methods. More-
over, if an increasing number of laboratories apply enzym-
atic techniques, the number of vendors of commercial
enzymatic assays will increase, leading to more competi-
tion, which will ultimately reduce the costs of these
assays. To bring this in a broader perspective, more
accurate and precise measurements of SCr will lead to a
reduction of the source of error in GFR estimates and
thus errors in the staging of renal failure. Considering the
number of patients that are misclassified in this study
when using an alkaline picrate technique, clinical labora-
tories should also consider the implications for overall
health costs, since patients are referred based on creatin-
ine based estimates of GFR [35].
Although this study is a theoretical analysis, it is one
of the few illustrating the consequences of variations in
SCr measurements on GFR estimation and CKD staging
for the individual patient. Since the majority of Dutch la-
boratories is included and we have a large heterogeneous
cohort of patients in which we tested our model, we are
able to give a good reflection of the consequences it
might have for daily clinical practice. Moreover, we have
studied creatinine values on 11 different levels against a
strong reference method; and the samples used, were all
recent instead of remote samples, which are frequently
used in other studies. Selection bias may have occurred,
since laboratories with too few analyses in the external
quality control program were excluded for further ana-
lysis in our patient cohort. Moreover, we applied the
MDRD formula in a patient cohort with an age range
from 19–106 years. This may have introduced bias since,
the MDRD has only been validated for patients from
19–70 years, and underestimates the GFR in patients
>70 years. However, in clinical practice, laboratories
automatically report eGFR’s each time a creatinine is
measured, also in patients older than 70 years, and clin-
ical decision making is often based on these estimates.
Conclusions
In conclusion, accurate and precise measurements of
SCr are required for a more reliable estimation of GFR
as support for reliable clinical decision making. Enzym-
atic techniques measure SCr with substantially less vari-
ability than Jaffe techniques as compared to ID-MS
reference values. This leads to more reliable estimation
of GFR and CKD staging. To allow improvement of reli-
ability of eGFR, specific enzymatic techniques to mea-
sure SCr are preferable over unspecific Jaffe techniques.
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